Plague vaccines

Current developments and future perspectives

Valentina A. Feodorova, Vladimir Motin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis.

Original languageEnglish
Article numbere36
JournalEmerging Microbes and Infections
Volume1
DOIs
StatePublished - 2012

Fingerprint

Plague Vaccine
Yersinia pestis
Subunit Vaccines
Plague
Humoral Immunity
Cellular Immunity
Vaccines
DNA

Keywords

  • Plague
  • Protective antigens
  • Vaccine
  • Yersinia pestis

ASJC Scopus subject areas

  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Drug Discovery
  • Epidemiology
  • Infectious Diseases

Cite this

Plague vaccines : Current developments and future perspectives. / Feodorova, Valentina A.; Motin, Vladimir.

In: Emerging Microbes and Infections, Vol. 1, e36, 2012.

Research output: Contribution to journalArticle

@article{cef0026be6544f0ab919b882bdf5545e,
title = "Plague vaccines: Current developments and future perspectives",
abstract = "Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis.",
keywords = "Plague, Protective antigens, Vaccine, Yersinia pestis",
author = "Feodorova, {Valentina A.} and Vladimir Motin",
year = "2012",
doi = "10.1038/emi.2012.34",
language = "English",
volume = "1",
journal = "Emerging Microbes and Infections",
issn = "2222-1751",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Plague vaccines

T2 - Current developments and future perspectives

AU - Feodorova, Valentina A.

AU - Motin, Vladimir

PY - 2012

Y1 - 2012

N2 - Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis.

AB - Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague, there is no safe and efficient vaccine against this devastating disease. A recently developed F1/V subunit vaccine candidate, which relies mainly on humoral immunity, showed promising results in animal studies; however, its efficacy in humans still has to be carefully evaluated. In addition, those developing next-generation plague vaccines need to pay particular attention to the importance of eliciting cell-mediated immunity. In this review, we analyzed the current progress in developing subunit, DNA and live carrier platforms of delivery by bacterial and viral vectors, as well as approaches for controlled attenuation of virulent strains of Y. pestis.

KW - Plague

KW - Protective antigens

KW - Vaccine

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=84878369905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878369905&partnerID=8YFLogxK

U2 - 10.1038/emi.2012.34

DO - 10.1038/emi.2012.34

M3 - Article

VL - 1

JO - Emerging Microbes and Infections

JF - Emerging Microbes and Infections

SN - 2222-1751

M1 - e36

ER -